Whistleblower Medicaid Fraud Attorneys

If you’ve become aware of Medicaid Fraud, the Whistleblower Firm of Nolan, Auerbach & White can help. Our Medicaid Fraud Attorneys represent and advocate for whistleblowers in lawsuits filed in Federal Court. We work with the Department of Justice while your case is under seal, as they confidentially investigate your claims.


EXPLORE YOUR OPTIONS


With over 25 years of experience and $6 billion collected and returned to taxpayers since the False Claims Act was amended in 1986, courageous Medicaid Whistleblowers call on our False Claims Act Lawyers with confidence.

Have You Witnessed Medicaid Fraud?

Contact the Medicaid Whistleblower Attorneys at Nolan, Auerbach & White to get started on a free and 100% confidential review of your important case. Call our Whistleblower Healthcare Fraud Attorneys at 800.372.8304 today. 


START A FREE CASE EVALUATION


Jump To Contents 

Medicaid Fraud Lawyers - The Whistleblower Firm

Protecting The Medicaid Fraud Whistleblower

The purpose of the Qui Tam provisions of the FCA is to encourage private individuals aware of Medicaid Fraud and Abuse to bring such information forward under a confidential and protected status. Our experienced team of Medicaid Fraud Lawyers at The Whistleblower Firm can advise you of your options and expectations.  Begin this important duty and service by scheduling a free review of your case. 

For many Medicaid Fraud Whistleblowers, it is possible to collect a percentage of what has been recovered as an award for this vital service. CMS Whistleblower rewards for Medicaid vary from 15-30 percent of the amount collected. 

LEARN MORE: Whistleblower Protection

Identifying Medicaid Fraud and Abuse

Fraudulent activity with Medicaid typically coincides with a violation of the False Claims Act. When you’re ready to explore your options as a potential whistleblower, our Medicaid Fraud Lawyers are here to confidentially discuss the details of your important case.   


CONTACT US


Medicaid Billing Fraud and the Problem of Incomplete Data

Because spending for the Medicaid program is projected to exceed $900 billion by fiscal year 2025, reducing Medicaid Fraud will save consequential taxpayer dollars. One of the biggest issues facing the Medicaid program is a lack of timely, accurate, and complete data on the front end, before payment to healthcare providers.  The work and oversight function of the Centers for Medicare and Medicaid Services (CMS) and its contractors are hampered in a “pay and chase” system when reimbursements are made to healthcare providers without any opportunity (other than edits) to ensure medical necessity, services actually delivered, appropriate coding, etc. 

Our Medicaid Fraud Attorneys at The Whistleblower Firm are ready to confidentially discuss your case, along with potential CMS whistleblower rewards (via federal and state qui tam lawsuits ) involved in Medicaid Fraud Lawsuits. Find out your options by calling us or filling out our online form

LEARN MORE: Medicaid Fraud Oversight Issues

Medicaid Drug Rebate Program

The Medicaid Rebate Program is one example of Medicaid Fraud. The scenario begins as a  beneficiary obtains a prescription drug from a participating pharmacy, which has purchased the drug in the marketplace from a manufacturer or wholesaler. The pharmacist submits a claim and then receives payment from the state Medicaid agency based on the state’s formula for typically (Average Wholesale Price) AWP less a percentage. 

The manufacturer then pays a rebate, each quarter, for all of its drugs reimbursed by Medicaid each quarter. In order to decrease the amounts owed to the states, some pharmaceutical companies misrepresent material facts in their quarterly submissions to the  Medicaid Rebate Program reporting, to include misrepresentation of the regulatory origin/status of their Brand Name Drugs, the Average Manufacturer Price (AMP), and/or the Best Price. 

The rebate for drugs is based in part on two prices submitted by the manufacturer to CMS each calendar quarter:

  1. Average Manufacturer Price (AMP) – the average price that a drugmaker receives in a given quarter for sales to wholesalers of a drug distributed in the retail class of trade. 
  2. Lowest Transaction Price or “Best Price” – charged to any buyer in the private market (and reflecting all rebates or discounts) during that quarter.

Responsibilities of Medicaid Beneficiaries

The AMP and the Best Price must be reported for each respective dosage form and strength of all prescription drugs purchased on behalf of Medicaid beneficiaries. Those prices, which remain confidential, serve as reference points in determining drugmakers’ rebate obligations.

CMS calculates the unit rebate amount (URA) for each covered drug using price data submitted by the drug manufacturers. Each quarter, each State Agency sends an invoice to each drug manufacturer/labeler, using the URA from CMS and the units dispensed for each drug (from its own records), to determine the actual rebate amounts due from the manufacturer. The manufacturer has 38 days from the day a State Agency sends an invoice to pay the rebate and avoid interest charges.

The Three Drug Categories for Rebates

In order to determine rebate amounts, the reporting requirements include designation of a drug’s status into one of three categories:

  1. Innovator Multiple Source Drug” is defined by statute as having “the meaning set forth in Section 1927(k)(7)(A)(ii) of the Act and shall include all Covered Outpatient Drugs approved under a New Drug Application (NDA), Product License Approval (PLA), Establishment License Approval (ELA) or Antibiotic Drug Approval (ADA). A Covered Outpatient Drug marketed by a cross-licensed producer or distributor under the approved NDA shall be included as an innovator multiple source drug when the drug product meets this definition.” 42 U.S.C. § 1396r-8(c)(1)(C)(k). In 42 CFR 447.502, CMS clarified that an Innovator Multiple Source type of drug includes an authorized generic drug including any labelers operating under the NDA. 
  2. “Single Source Drug” is defined by statute as “a covered outpatient drug which is produced or distributed under an original new drug application approved by the Food and Drug Administration, including a drug product marketed by any cross-licensed producers or distributors operating under the New Drug Application (NDA).” It also includes a Covered Outpatient Drug approved under a PLA, ELA or ADA. 
  3. “Non-Innovator Multiple Source Drug” is defined by statute as “a multiple source drug that is not an innovator multiple source drug.”

A Single Source, and an Innovator Multiple Source Drug, are both commonly known and referred to herein as a “Brand Name Drug,” while a Non-Innovator Multiple Source Drug is commonly known as, and referred to herein as a “Generic Drug.”

CMS Rebate Formula for Drugs

For Brand Name drugs, the rebate consists of two components: 

  1. The manufacturer must pay a “basic rebate” equal to the greater of (i) 15.1 percent of the “Average Manufacturer Price” (AMP) of the drug or (ii) the difference between the drug’s AMP and its “Best Price” (BP) whichever is greater; plus  
  2. The manufacturer must pay an “additional” rebate to the extent that the AMP of the drug has increased faster than the rate of inflation since the launch of the product.

The manufacturers of Brand Name Drugs almost always owe the additional rebate. In 2003, for instance, the drugs for which an additional rebate was owed represented about 84 percent of Medicaid’s reimbursements for brand-name prescription drugs. In its report, “The Rebate Medicaid receives as Brand-Name Prescription Drugs” dated June 21, 2005, the Congressional Budget Office of the United States, estimated that in 2003, the average rebate received by Medicaid for brand-name prescription drugs was 31.4% of the AMP.

The rebate for Generic Drugs is much less than for Brand Name Drugs. It is a base rate of 11% of AMP, with no additional rebate. In contrast, the total rebates due for Brand Name Drugs have typically been within a couple of points of 31% of AMP, a difference of roughly twenty (20) percent.

Our Medicaid Fraud Lawyers can help clarify whether or not fraud exists in each scenario. Contact us for a free and 100% confidential case review.

Medicaid Fraud Lawsuits and Other Cases We Handle

Our law firm representing whistleblowers has the experience to discuss in-depth areas of Healthcare Fraud. Our Medicaid Fraud Attorneys are advocates for many CMS whistleblowing clients and those exposing other fraud that may include:

Explore your options as a CMS whistleblower by filling out our confidential online form for potential clients or give Nolan, Auerbach, and White and our experienced team of Qui Tam Medicaid Fraud Attorneys a call today at 800.372.8304.


CONTACT THE WHISTLEBLOWER FIRM


Nolan Auerbach and White

Contact a Medicaid Fraud Law Firm Representing Whistleblowers

Does your case have merit? We invite you to confidentially submit your facts to our experienced Medicaid Fraud Lawyers for a free case evaluation.

Join the many whistleblower heroes we have represented. We’re here to help you take the next courageous step forward by doing the right thing and pursuing justice. We understand the pressure of becoming aware of significant fraud, and we are here to alleviate that pressure and turn a negative situation at work into a positive outcome for you. 

You are protected by law against retaliation and whistleblowers can receive a percentage of the funds recovered from the Defendant under the FCA.

Get started by filling out our online form, or call our team of experienced Medicaid Fraud Lawyers at 800.372.8304.

 


EXPLORE HOW WE CAN HELP YOU


Frequently Asked Questions About Medicaid Fraud Lawsuits


What Kinds of CMS Whistleblower Rewards Exist for Exposing Medicaid Fraud?

 

Eligible whistleblowers may receive between 15-30 percent of the amount collected in Medicaid Fraud cases, through the qui tam provisions of federal and state statutes. To learn more about the potential of your knowledge, obtain quick feedback, and learn what we can do for you, begin a free evaluation of your important case.


What Percentage of False Claims Act Cases Are Successful?

 

The National Conference of State Legislatures notes that “about 80 percent of all fraud cases won under the FCA are a direct result of whistleblower lawsuits.” If you are aware of Medicaid fraud, contact our Healthcare Fraud Law Firm to confidentially discuss more with a Medicaid Fraud Attorney.

Kathleen Hawkins

Dignity Health
$37 million

Kathleen Hawkins, RN MSN, had been employed by Defendant, Catholic Healthcare West (CHW) for approximately 6 years when she decided she had had enough of trying to change the hospital system from within.

CHW, a California not-for-profit corporation that operated hospitals in California, Arizona, and Nevada, was at the time the eighth largest hospital system in the nation and the largest not-for-profit hospital provider in California.

CLICK FOR MORE


Warning: Illegal string offset 'title' in /srv/users/nawprod/apps/whistleblowerfirm/public/wp-content/themes/naw-child/blocks/gutenberg/story-carousel-section.php on line 75

Joe Strom

Johnson & Johnson
$184 Million

Joe Strom contacted us in 2005. We were very grateful that he did. We immediately formed an all-star legal team and a process to stop a very harmful pharmaceutical marketing strategy. It was this process we set into motion that ultimately returned hundreds of millions of dollars to the U.S. Treasury, and a portion of that, very well-deserved, into Joe’s bank account.

Joe told us a very troubling story about the off-label promotion of a pharmaceutical drug for patients who already suffered from chronic heart failure.

CLICK FOR MORE


Warning: Illegal string offset 'title' in /srv/users/nawprod/apps/whistleblowerfirm/public/wp-content/themes/naw-child/blocks/gutenberg/story-carousel-section.php on line 75

Bruce A. Moilan Sr.

$27 Million

Bruce Moilan was a seasoned hospital systems expert by the time he contacted our Firm. At the time he decided to file his qui tam lawsuit, he was employed by South Texas Health System as a System Director for Materials Management. In this position, he oversaw $24 million in annual purchases of supplies and equipment and helped determine budget, reduction and cost analysis throughout the contract bidding and negotiations process. His job was to insure proper implementation for purchasing, receiving and management of inventory, for McAllen Hospitals, L.P.

CLICK FOR MORE


Warning: Illegal string offset 'title' in /srv/users/nawprod/apps/whistleblowerfirm/public/wp-content/themes/naw-child/blocks/gutenberg/story-carousel-section.php on line 75
Description
Description
Description

Am I potential whistleblower that matches up well with our firm?

We only want to represent amazing people.

How much will I make?

We cannot guarantee anything, but we will deliver on this promise: we will give you feedback and a prognosis within 48 hours of your submission of all details to us. We are the first healthcare fraud qui tam law firm, and have been doing only healthcare fraud whistleblower lawsuits for decades-so you can expect as accurate a picture as is possible.

Are my communications with you confidential?

They are 100% confidential. If we do not take your case, your information becomes inaccessible. We have no interest in it. Besides, it is protected by the attorney-client privilege under our lawyer regulations, and we would lose our license if we were to disclose one iota of information about you or your potential case.

    Contact Us

    Contact Us

    The more detailed the response, the more likely it is that we will be able to evaluate and determine if your potential False Claims Act case falls within our case requirements. IF IT DOES, WE WILL RESPOND TO YOU WITHIN 24 HOURS. (Names of potential defendants are not necessary at this point, should you feel more comfortable omitting them.) By law, all communications to us are 100% confidential.

    No. of Employees at the Company?
    Please read the following statement and then click "Send Form":

    Any response to your e-mail will be solely to communicate about our possible representation of you under the qui tam provisions of the False Claims Act. All e-mails submitted to us, whether we take your case or not, are 100% confidential. If we do not respond to your e-mail, then you have communicated information which we cannot address because it appears to fall outside of the False Claims Act or our case requirements.